Zipalertinib
Selective oral EGFR exon 20 inhibitor; FDA BLA submitted 2024. FDA submission 2024 — next exon 20 approval candidate
Description
Scientific Overview: Selective oral EGFR exon 20 inhibitor; FDA BLA submitted 2024. FDA submission 2024 — next exon 20 approval candidate
Mechanism of Action: EGFR Exon 20 Insertion TKI
Purity: ≥99% | Molecular Formula: C28H32FN5O4
For Research Use Only. Not intended for diagnostic, therapeutic, or clinical applications.
Additional information
| Effect | EGFR Exon 20 Insertion TKI |
|---|---|
| Purity | ≥99% |
| Molecular Formula | C28H32FN5O4 |
| CAS Number |
